+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

lisocabtagene maraleucel

  • ID: 4775420
  • Report
  • 30 pages
  • Datamonitor Healthcare
1 of 2
Drug Overview
Lisocabtagene maraleucel (also known as JCAR017; Celgene) will be the third autologous chimeric antigen receptor T-cell (CAR-T) therapy to reach the diffuse large B-cell lymphoma (DLBCL) market following the launches of approved CAR-T drugs Kymriah (tisagenlecleucel; Novartis) and Yescarta (axicabtagene ciloleucel; Gilead). Lisocabtagene maraleucel has demonstrated comparable efficacy to Kymriah and Yescarta and a positive tolerability profile in the Phase I TRANSCEND trial (ClinicalTrials.gov identifier: NCT02631044) in relapsed/refractory DLBCL patients. These results will help lisocabtagene maraleucel to compete with the approved CAR-T therapies, as well as several pipeline regimens targeting relapsed/refractory patients.
Lisocabtagene maraleucel is an autologous T-cell therapy genetically engineered to express a CAR targeting cluster of differentiation (CD)19. CD19 is only expressed on B cells, thus it is an attractive target in B-cell leukemias and B-cell lymphomas. Studies suggest CD19 CAR-T cell-based immunotherapies effectively recognize and kill CD19-positive target cells and result in a high clinical response rate in the treatment of refractory B-cell malignancies, including DLBCL.

Analyst Outlook
Lisocabtagene maraleucel (also known as JCAR017; Celgene) will be the third autologous chimeric antigen receptor T-cell (CAR-T) therapy to reach the diffuse large B-cell lymphoma (DLBCL) market following the launches of approved CAR-T drugs Kymriah (tisagenlecleucel; Novartis) and Yescarta (axicabtagene ciloleucel; Gilead). Lisocabtagene maraleucel has demonstrated comparable efficacy to Kymriah and Yescarta and a positive tolerability profile in the Phase I TRANSCEND trial (ClinicalTrials.gov identifier:NCT02631044) in relapsed/refractory DLBCL patients. These results will help lisocabtagene maraleucel to compete with the approved CAR-T therapies, as well as several pipeline regimens targeting relapsed/refractory patients.
Note: Product cover images may vary from those shown
2 of 2
OVERVIEW
Drug Overview
Product Profiles
lisocabtagene maraleucel : NHL: Follicular lymphoma (FL)
lisocabtagene maraleucel : NHL: Diffuse large B-cell lymphoma (DLBCL)

LIST OF FIGURES
Figure 1: Lisocabtagene maraleucel for follicular lymphoma – SWOT analysis
Figure 2: The authors drug assessment summary of lisocabtagene maraleucel for follicular lymphoma
Figure 3: The authors drug assessment summary of lisocabtagene maraleucel for follicular lymphoma
Figure 4: Lisocabtagene maraleucel sales for follicular lymphoma across the US, Japan, and five major EU markets, by country, 2017–26
Figure 5: Lisocabtagene maraleucel for diffuse large B-cell lymphoma – SWOT analysis
Figure 6: The authors drug assessment summary for lisocabtagene maraleucel in diffuse large B-cell lymphoma
Figure 7: The authors drug assessment summary for lisocabtagene maraleucel in diffuse large B-cell lymphoma
Figure 8: Lisocabtagene maraleucel sales for diffuse large B-cell lymphoma across the US, Japan, and five major EU markets, by country, 2017–26

LIST OF TABLES
Table 1: Lisocabtagene maraleucel drug profile
Table 2: Lisocabtagene maraleucel ongoing pivotal trial in follicular lymphoma
Table 3: Lisocabtagene maraleucel sales for follicular lymphoma across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 4: Lisocabtagene maraleucel drug profile
Table 5: Lisocabtagene maraleucel pivotal trial data in diffuse large B-cell lymphoma
Table 6: Lisocabtagene maraleucel ongoing pivotal trial in diffuse large B-cell lymphoma
Table 7: Lisocabtagene maraleucel sales for diffuse large B-cell lymphoma across the US, Japan, and five major EU markets, by country ($m), 2017–26
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Order Online - visit: https://www.researchandmarkets.com/reports/4775420
Adroll
adroll